130 related articles for article (PubMed ID: 31415805)
21. Development of Recombinant Infectious Hepatitis E Virus Harboring the nanoKAZ Gene and Its Application in Drug Screening.
Primadharsini PP; Nagashima S; Nishiyama T; Takahashi M; Murata K; Okamoto H
J Virol; 2022 Mar; 96(6):e0190621. PubMed ID: 35107380
[TBL] [Abstract][Full Text] [Related]
22. Mitochondrial electron transport chain complex III sustains hepatitis E virus replication and represents an antiviral target.
Qu C; Zhang S; Wang W; Li M; Wang Y; van der Heijde-Mulder M; Shokrollahi E; Hakim MS; Raat NJH; Peppelenbosch MP; Pan Q
FASEB J; 2019 Jan; 33(1):1008-1019. PubMed ID: 30070932
[TBL] [Abstract][Full Text] [Related]
23. The macrolide antibiotic azithromycin potently inhibits hepatitis E virus in cell culture models.
Miao Z; Zhang R; Yu P; Li Y; Pan Q; Li Y
Int J Antimicrob Agents; 2021 Sep; 58(3):106383. PubMed ID: 34157403
[TBL] [Abstract][Full Text] [Related]
24. Knockdown of RIPK1 Markedly Exacerbates Murine Immune-Mediated Liver Injury through Massive Apoptosis of Hepatocytes, Independent of Necroptosis and Inhibition of NF-κB.
Suda J; Dara L; Yang L; Aghajan M; Song Y; Kaplowitz N; Liu ZX
J Immunol; 2016 Oct; 197(8):3120-3129. PubMed ID: 27605011
[TBL] [Abstract][Full Text] [Related]
25. Pan-Genotype Hepatitis E Virus Replication in Stem Cell-Derived Hepatocellular Systems.
Wu X; Dao Thi VL; Liu P; Takacs CN; Xiang K; Andrus L; Gouttenoire J; Moradpour D; Rice CM
Gastroenterology; 2018 Feb; 154(3):663-674.e7. PubMed ID: 29277559
[TBL] [Abstract][Full Text] [Related]
26. Cutthroat trout virus as a surrogate in vitro infection model for testing inhibitors of hepatitis E virus replication.
Debing Y; Winton J; Neyts J; Dallmeier K
Antiviral Res; 2013 Oct; 100(1):98-101. PubMed ID: 23916729
[TBL] [Abstract][Full Text] [Related]
27. Systematic identification of hepatitis E virus ORF2 interactome reveals that TMEM134 engages in ORF2-mediated NF-κB pathway.
Tian Y; Huang W; Yang J; Wen Z; Geng Y; Zhao C; Zhang H; Wang Y
Virus Res; 2017 Jan; 228():102-108. PubMed ID: 27899274
[TBL] [Abstract][Full Text] [Related]
28. Potent Inhibition of Hepatitis E Virus Release by a Cyclic Peptide Inhibitor of the Interaction between Viral Open Reading Frame 3 Protein and Host Tumor Susceptibility Gene 101.
Anang S; Kaushik N; Hingane S; Kumari A; Gupta J; Asthana S; Shalimar ; Nayak B; Ranjith-Kumar CT; Surjit M
J Virol; 2018 Oct; 92(20):. PubMed ID: 30068652
[TBL] [Abstract][Full Text] [Related]
29. Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro.
Nishiyama T; Kobayashi T; Jirintai S; Nagashima S; Primadharsini PP; Nishizawa T; Okamoto H
Antiviral Res; 2019 Oct; 170():104570. PubMed ID: 31362004
[TBL] [Abstract][Full Text] [Related]
30. Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB.
Biermer M; Puro R; Schneider RJ
J Virol; 2003 Apr; 77(7):4033-42. PubMed ID: 12634363
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis E Virus Mutations: Functional and Clinical Relevance.
van Tong H; Hoan NX; Wang B; Wedemeyer H; Bock CT; Velavan TP
EBioMedicine; 2016 Sep; 11():31-42. PubMed ID: 27528267
[TBL] [Abstract][Full Text] [Related]
32. Distinct Antiviral Potency of Sofosbuvir Against Hepatitis C and E Viruses.
Wang W; Hakim MS; Nair VP; de Ruiter PE; Huang F; Sprengers D; Van Der Laan LJ; Peppelenbosch MP; Surjit M; Pan Q
Gastroenterology; 2016 Dec; 151(6):1251-1253. PubMed ID: 27815000
[No Abstract] [Full Text] [Related]
33. Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication.
Zhou X; Xu L; Wang Y; Wang W; Sprengers D; Metselaar HJ; Peppelenbosch MP; Pan Q
Antiviral Res; 2015 Dec; 124():11-9. PubMed ID: 26526587
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Hepatitis E Virus Spread by the Natural Compound Silvestrol.
Glitscher M; Himmelsbach K; Woytinek K; Johne R; Reuter A; Spiric J; Schwaben L; Grünweller A; Hildt E
Viruses; 2018 Jun; 10(6):. PubMed ID: 29865243
[TBL] [Abstract][Full Text] [Related]
35. Three Distinct Reporter Systems of Hepatitis E Virus and Their Utility as Drug Screening Platforms.
Primadharsini PP; Nagashima S; Nishiyama T; Okamoto H
Viruses; 2023 Sep; 15(10):. PubMed ID: 37896767
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of hepatitis E virus replication by zinc-finger antiviral Protein synergizes with IFN-β.
Yu W; Ji H; Long F; Chen S; He Q; Xia Y; Cong C; Yang C; Wei D; Huang F
J Viral Hepat; 2021 Aug; 28(8):1219-1229. PubMed ID: 33894039
[TBL] [Abstract][Full Text] [Related]
37. NF-κB-Independent Role of IKKα/IKKβ in Preventing RIPK1 Kinase-Dependent Apoptotic and Necroptotic Cell Death during TNF Signaling.
Dondelinger Y; Jouan-Lanhouet S; Divert T; Theatre E; Bertin J; Gough PJ; Giansanti P; Heck AJ; Dejardin E; Vandenabeele P; Bertrand MJ
Mol Cell; 2015 Oct; 60(1):63-76. PubMed ID: 26344099
[TBL] [Abstract][Full Text] [Related]
38. Survival of Single Positive Thymocytes Depends upon Developmental Control of RIPK1 Kinase Signaling by the IKK Complex Independent of NF-κB.
Webb LV; Barbarulo A; Huysentruyt J; Vanden Berghe T; Takahashi N; Ley S; Vandenabeele P; Seddon B
Immunity; 2019 Feb; 50(2):348-361.e4. PubMed ID: 30737145
[TBL] [Abstract][Full Text] [Related]
39. Ivermectin effectively inhibits hepatitis E virus replication, requiring the host nuclear transport protein importin α1.
Li Y; Miao Z; Li P; Zhang R; Kainov DE; Ma Z; de Man RA; Peppelenbosch MP; Pan Q
Arch Virol; 2021 Jul; 166(7):2005-2010. PubMed ID: 33987753
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic targets for the treatment of hepatitis E virus infection.
Kenney SP; Meng XJ
Expert Opin Ther Targets; 2015; 19(9):1245-60. PubMed ID: 26073772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
